These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3742063)

  • 1. Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.
    Harris AL; Cantwell BM; Sainsbury JR; Needham G; Evans RG; Dawes PJ; Wilson R; Farndon J
    Breast Cancer Res Treat; 1986; 7 Suppl():S41-4. PubMed ID: 3742063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
    Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
    Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer.
    Harris AL; Cantwell BM; Carmichael J; Dawes P; Robinson A; Farndon J; Wilson R
    Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1105-11. PubMed ID: 2759165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
    Rose C; Kamby C; Mouridsen HT; Bastholt L; Brincker H; Skovgaard-Poulsen H; Andersen AP; Loft H; Dombernowsky P; Andersen KW
    Breast Cancer Res Treat; 1986; 7 Suppl():S45-50. PubMed ID: 3527306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.
    Harris AL; Powles TJ; Smith IE
    Cancer Res; 1982 Aug; 42(8 Suppl):3405s-3408s. PubMed ID: 7083207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
    Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA
    Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day].
    Bonneterre J; Coppens H; Mauriac L; Rouesse J; Fargeot P; Metz R; Armand JP; Mathieu A; Tubiana M; Cappelaere P
    Acta Clin Belg Suppl; 1986; 11():41-8. PubMed ID: 3521171
    [No Abstract]   [Full Text] [Related]  

  • 8. Aminoglutethimide as second line therapy in advanced breast cancer.
    Elomaa I; Blomqvist C; Rissanen P
    Breast Cancer Res Treat; 1986; 7 Suppl():S51-4. PubMed ID: 3017481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical studies with aminoglutethimide in advanced breast carcinoma.
    Harvey HA; Lipton A; Santen RJ
    Acta Clin Belg Suppl; 1986; 11():29-40. PubMed ID: 3459321
    [No Abstract]   [Full Text] [Related]  

  • 10. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
    Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
    Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer.
    Mercer PM; Ebbs SR; Fraser SC; Coltart RS; Bates T
    Eur J Surg Oncol; 1993 Jun; 19(3):254-8. PubMed ID: 8314383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
    Höffken K; Kempf H; Miller AA; Miller B; Schmidt CG; Faber P; Kley HK
    Cancer Treat Rep; 1986 Oct; 70(10):1153-7. PubMed ID: 3756937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic results obtained with aminoglutethimide in advanced-stage breast cancer. Factors predictive of a response].
    Paridaens RJ; Arrigo C; Heuson JC
    Acta Clin Belg Suppl; 1986; 11():18-28. PubMed ID: 3459320
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose aminoglutethimide plus steroid replacement in advanced breast cancer patients resistant to conventional therapies.
    Crivellari D; Galligioni E; Frustaci S; Gasparini G; Vaccher E; Lo Re G; Talamini R; Monfardini S; Ambroso G
    Cancer Invest; 1989; 7(2):113-6. PubMed ID: 2790534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
    Bezwoda WR; Derman DP; Browde S; Goss G; Lange M
    S Afr Med J; 1984 Sep; 66(10):372-4. PubMed ID: 6484759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status.
    Bezwoda WR; Dansey RD; Hesdorffer CS; Browde S
    S Afr Med J; 1987 Jul; 72(2):107-9. PubMed ID: 3616780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer.
    Gennatas CS; Kalovidouris A; Paraskevas GA; Kouvaris J; Trichopoulos D; Papavasiliou C
    Radiother Oncol; 1987 Jul; 9(3):217-20. PubMed ID: 3628857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast].
    Bonneterre J; Pion JM; Demaille A
    Bull Cancer; 1987; 74(3):241-7. PubMed ID: 3304478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
    Dowsett M; Harris AL; Smith IE; Jeffcoate SL
    Br J Cancer; 1984 Sep; 50(3):357-61. PubMed ID: 6540595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of breast cancer.
    Cohen IA; Keller JH; Abate MA
    Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.